Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04791358

Decision Impact Trial of KidneyIntelX

Sponsor: Renalytix AI, Inc.

View on ClinicalTrials.gov

Summary

The current trial is designed to evaluate how the results of KidneyIntelX test impacts on the clinical management of type 2 diabetes patients identified as increased risk for rapid kidney function decline within 5-years.

Official title: A Prospective Decision Impact Trial of KidneyIntelX in Patients With Type 2 Diabetes and Existing Chronic Kidney Disease

Key Details

Gender

All

Age Range

23 Years - Any

Study Type

OBSERVATIONAL

Enrollment

1500

Start Date

2021-11-01

Completion Date

2024-12-01

Last Updated

2024-04-12

Healthy Volunteers

No

Interventions

DIAGNOSTIC_TEST

KidneyIntelX

KidneyIntelX is an in-vitro diagnostic that enables accurate risk prediction of progressive decline in kidney function and kidney failure in patients with type 2 diabetes and existing CKD at stages 1-3 (eGFR of 30 to 59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 and uACR ≥ 30 mg/g).

Locations (1)

Delmar Family Medicine

Slingerlands, New York, United States